Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Jul
18
2016
House Passes GE Labeling Bill; Obama Expected to Sign Mintz
Apr
22
2020
FDA Continues Its Diverse Agency Actions in Response to COVID-19 Pandemic Mintz
Oct
5
2023
Courts Continue to Grapple with the Causation Standard for False Claims Act Suits Based on Alleged Kickback Schemes, While the Supreme Court Stays on the Sidelines Mintz
Aug
31
2016
6-Month Notice from a Biosimilar Sponsor Always Required — Says Federal Circuit Mintz
Nov
17
2023
Indecent Disclosure: FTC Slams Advertisers and Influencers for Failure to Divulge Material Connections Mintz
Jan
12
2017
FDA Finalizes Tobacco Product Intended Use Rules, Under a Risk of Rescission by Congress Mintz
Jan
17
2017
FDA’s Enforcement Priorities Likely to Change in 2017 and Other “Unknowable Knowns” Mintz
Feb
22
2024
Mintz IRA Update — The IRA in 2024: The Medicare Drug Price Negotiation Program in Full Swing and Other Developments Mintz
Feb
27
2024
CMS Releases Part Two of Guidance for the Inflation Reduction Act’s Medicare Prescription Payment Plan Mintz
Sep
1
2020
Bioethics in a Pandemic: Learning from the Past Mintz
Sep
15
2020
Trump Signs Executive Orders Aimed at Tying Domestic Drug Prices to Foreign Prices Mintz
Mar
16
2017
21st Century Cures Act Developments: FDA Proposes Class II Device Exemptions Mintz
Apr
16
2024
Navigating Health Tech: Regulations for AI/ML in Medical Devices and Software [Video] Mintz
Apr
22
2024
NY AG Launches Greenwashing Lawsuit Against Beef Producer Mintz
Apr
25
2024
Federal Circuit Affirms Obviousness of Rifaximin Polymorph Patents and Denial of Motion to Modify Judgment After Post-Trial Patented Indication Carve Out Mintz
Jun
29
2017
Massachusetts House and Senate Tackle Marijuana Mintz
Aug
15
2017
The Past, Present, and Future of Government Regulation of Off-Label Communications – Part 3 Mintz
Mar
5
2012
Energy and Environment Update - March 4, 2012 Mintz
Apr
17
2012
MA Senate Bill Would Revise Incentives for Renewable Energy Development Mintz
Dec
11
2012
Energy & Environmental Law Update – December 11, 2012 Mintz
Jan
20
2013
Climate Change: Emerging Law of Adaptation Mintz
Mar
16
2013
State Department Announces $6 Billion for Geothermal in Southeast Asia Mintz
May
6
2021
FDA Ups the Ante and Sends First Notice of Noncompliance for Failure to Submit Clinical Trial Results Mintz
Jun
1
2021
Panel Discussion Among Government Lawyers Provides Key Insights into the Future of FCA Enforcement Mintz
Jun
7
2021
FDA’s Unapproved Drugs Initiative Revived, with Gusto! Mintz
Jun
4
2013
Delta Finds Reprieve in State Court, but Not Everyone Will Get to Fly the Friendly Skies Mintz
Aug
9
2013
Deepwater Wind, Wins First Federal Auction for Commercial Offshore Wind Development Mintz
Jul
20
2018
CMS Proposes to Reduce Payments for New Drugs under Medicare Part B Mintz
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins